Cdk4 disruption renders primary mouse cells resistant to oncogenic transformation, leading to Arf/p53-independent senescence

Genes and Development

Volumn 16, Issue 22, 2002, Pages 2923-2934

  Zou, Xianghong ^a   Ray, Dipankar ^a   Aziyu, Aileen ^a   Christov, Konstantin ^a   Boiko, Alexander D ^a,b   Gudkov, Andrei V ^a,b   Kiyokawa, Hiroaki ^a  

^a UNIVERSITY OF ILLINOIS   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Cancer; Cdk; Cell cycle; Cyclin; Immortalization; Ink4a; P21; Ras; Stability

Indexed keywords

CELL PROTEIN; CYCLIN D; CYCLIN DEPENDENT KINASE 4; ONCOPROTEIN; PROTEIN INK4A; PROTEIN P21; PROTEIN P53; RNA; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CANCER RESISTANCE; CARCINOGENESIS; CELL IMMORTALIZATION; CELL PROLIFERATION; CELL TRANSFORMATION; CONTROLLED STUDY; ENZYME ACTIVATION; FIBROBLAST; GENE ACTIVATION; GENE DISRUPTION; GENE EXPRESSION; GENE INACTIVATION; GENE REPRESSION; GENETIC TRANSFORMATION; MOUSE; NONHUMAN; NUDE MOUSE; NULL ALLELE; ONCOGENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN STABILITY; SENESCENCE; WILD TYPE;

ADP-RIBOSYLATION FACTOR 1; ANIMALS; CARCINOGENICITY TESTS; CELL AGING; CELL TRANSFORMATION, NEOPLASTIC; CELLS, CULTURED; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASES; CYCLINS; FIBROBLASTS; MICE; MICE, INBRED STRAINS; MICE, MUTANT STRAINS; MICE, NUDE; ONCOGENE PROTEINS, VIRAL; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RNA, SMALL INTERFERING; TUMOR SUPPRESSOR PROTEIN P53;

ANIMALIA; MUS MUSCULUS;

EID: 0037112178     PISSN: 08909369     EISSN: None     Source Type: Journal    
DOI: 10.1101/gad.1033002     Document Type: Article

References (74)

1. Blain, S.W., Montalvo, E., and Massague, J. 1997. Differential interaction of the cyclin-dependent kinase (Cdk) inhibitor p27Kipl with cyclin A-Cdk2 and cyclin D2-Cdk4. J. Biol. Chem. 272: 25863-25872.
2. Boyer, S.N., Wazer, D.E., and Band, V. 1996. E7 protein of human papilloma virus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome pathway. Cancer Res. 56: 4620-4624.
3. Boylan, J.F., Sharp, D.M., Leffet, L., Bowers, A., and Pan, W. 1999. Analysis of site-specific phosphorylation of the retinoblastoma protein during cell cycle progression. Exp. Cell Res. 248: 110-114.
4. Carnero, A., Hudson, J.D., Price, C.M., and Beach, D.H. 2000. p16INK4A and p19ARF act in overlapping pathways in cellular immortalization. Nat. Cell Biol. 2: 148-155.
5. Chang, B.D., Xuan, Y., Broude, E.V., Zhu, H., Schott, B., Fang, J., and Roninson, I.B. 1999. Role of p53 and p21waf1/cip1 in senescence-like terminal proliferation arrest induced in human tumor cells by chemotherapeutic drugs. Oncogene 18: 4808-4818.
6. Coats, S., Whyte, P., Fero, M.L., Lacy, S., Chung, G., Randel, E., Firpo, E., and Roberts, J.M. 1999. A new pathway for mitogen-dependent cdk2 regulation uncovered in p27(Kipl)-deficient cells. Curr. Biol. 9: 163-173.
7. Connell-Crowley, L., Harper, J.W., and Goodrich, D.W. 1997. Cyclin D1/Cdk4 regulates retinoblastoma protein-mediated cell cycle arrest by site-specific phosphorylation. Mol. Biol. Cell 8: 287-301.
8. Dannenberg, J.H., van Rossum, A., Schuijff, L., and te Riele, H. 2000. Ablation of the retinoblastoma gene family deregulates G(1) control causing immortalization and increased cell turnover under growth-restricting conditions. Genes & Dev. 14:3051-3064.
9. de Stanchina, E., McCurrach, M.E., Zindy, F., Shieh, S.Y., Ferbeyre, G., Samuelson, A.V., Prives, C., Roussel, M.F., Sherr, C.J., and Lowe, S.W. 1998. E1A signaling to p53 involves the p19(ARF) tumor suppressor. Genes & Dev. 12: 2434-2442.
10. Dimri, G.P., Lee, X., Basile, G., Acosta, M., Scott, G., Roskelley, C., Medrano, E.E., Linskens, M., Rubelj, I., Pereira-Smith, O., et al. 1995. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc. Natl. Acad. Sci. 92: 9363-9367.
11. Dyson, N., Howley, P.M., Munger, K., and Harlow, E. 1989. The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 243: 934-937.
12. Ewen, M.E., Sluss, H.K., Sherr, C.J., Matsushime, H., Kato, J., and Livingston, D.M. 1993. Functional interactions of the retinoblastoma protein with mammalian D-type cyclins. Cell 73: 487-497.
13. Ferbeyre, G., de Stanchina, E., Lin, A.W., Querido, E., McCurrach, M.E., Hannon, G.J., and Lowe, S.W. 2002. Oncogenic ras and p53 cooperate to induce cellular senescence. Mol. Cell Biol. 22: 3497-3508.
14. Fry, D.W., Bedford, D.C., Harvey, P.H., Fritsch, A., Keller, P.R., Wu, Z., Dobrusin, E., Leopold, W.R., Fattaey, A., and Garrett, M.D. 2001. Cell cycle and biochemical effects of PD 0183812. A potent inhibitor of the cyclin D-dependent kinases CDK4 and CDK6. J. Biol. Chem. 276: 16617-16623.
15. Funk, J.O., Waga, S., Harry, J.B., Espling, E., Stillman, B., and Galloway, D.A. 1997. Inhibition of CDK activity and PCNA-dependent DNA replication by p21 is blocked by interaction with the HPV-16 E7 oncoprotein. Genes & Dev. 11: 2090-2100.
16. Hanahan, D. and Weinberg, R.A. 2000. The hallmarks of cancer. Cell 100: 57-70.
17. Hartwell, L.H. and Kastan, M.B. 1994. Cell cycle control and cancer. Science 266: 1821-1828.
18. Hirama, T. and Koeffler, H.P. 1995. Role of the cyclin-dependent kinase inhibitors in the development of cancer. Blood 86:841-854.
19. Honma, T., Yoshizumi, T., Hashimoto, N., Hayashi, K., Kawanishi, N., Fukasawa, K., Takaki, T., Ikeura, C., Ikuta, M., Suzuki-Takahashi, I., et al. 2001. A novel approach for the development of selective Cdk4 inhibitors: Library design based on locations of Cdk4 specific amino acid residues. J. Med. Chem. 44: 4628-4640.
20. Hunter, T. 1997. Oncoprotein networks. Cell 88: 333-346.
21. Johnstone, R.W., Ruefli, A.A., and Lowe, S.W. 2002. Apoptosis: A link between cancer genetics and chemotherapy. Cell 108: 153-164.
22. Kamb, A., Gruis, N.A., Weaver-Feldhaus, J., Liu, Q., Harshman, K., Tavtigian, S.V., Stockert, E., Day III, R.S., Johnson, B.E., and Skolnick, M.H. 1994. A cell cycle regulator potentially involved in genesis of many tumor types. Science 264: 436-440.
23. Kamijo, T., Zindy, F., Roussel, M.F., Quelle, D.E., Downing, J.R., Ashmun, R.A., Grosveld, G., and Sherr, C.J. 1997. Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell 91: 649-659.
24. Kato, J., Matsushime, H., Hiebert, S.W., Ewen, M.E., and Sherr, C.J. 1993. Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase CDK4. Genes & Dev. 7: 331-342.
25. Khatib, Z.A., Matsushime, H., Valentine, M., Shapiro, D.N., Sherr, C.J., and Look, A.T. 1993. Coamplification of the CDK4 gene with MDM2 and GLI in human sarcomas. Cancer Res. 53: 5535-5541.
26. Kitagawa, M., Higashi, H., lung, H.K., Suzuki-Takahashi, I., Ikeda, M., Tamai, K., Kato, J., Segawa, K., Yoshida, E., Nishimura, S., et al. 1996. The consensus motif for phosphorylation by cyclin D1-Cdk4 is different from that for phosphorylation by cyclin A/E-Cdk2. EMBO J. 15: 7060-7069.
27. Kiyokawa, H. 2002. Cell cycle control and cell fate determination: In vivo roles of G1 cyclin-dependent kinases and inhibitors. In Recent research developments in molecular & cellular biology, Vol. 2 (ed. S.G. Pandalai). Research Signpost, Trivandrum, India (In press).
28. Kiyokawa, H. and Koff, A. 1998. Roles of cyclin -dependent kinase inhibitors: Lessons from knockout mice. Curr. Top. Microbiol. Immunol. 227: 105-120.
29. Kiyono, T., Foster, S.A., Koop, J.I., McDougall, J.K., Galloway, D.A., and Klingelhutz, A.J. 1998. Both Rb/p16INK4a inactivation and telomerase activity are required to immortalize human epithelial cells. Nature 396: 84-88.
30. Krimpenfort, P., Quon, K.C., Mooi, W.J., Loonstra, A., and Berns, A. 2001. Loss of p16Ink4a confers susceptibility to metastatic melanoma in mice. Nature 413: 83-86.
31. LaBaer, J., Garrett, M.D., Stevenson, L.F., Slingerland, J.M., Sandhu, C., Chou, H.S., Fattaey, A., and Harlow, E. 1997. New functional activities for the p21 family of CDK inhibitors. Genes & Dev. 11: 847-862.
32. Leng, X., Noble, M., Adams, P.D., Qin, J., and Harper, J.W. 2002. Reversal of growth suppression by p107 via direct phosphorylation by cyclin D1/cyclin-dependent kinase 4. Mol. Cell Biol. 22: 2242-2254.
33. Malumbres, M., Perez, D.C., I, Hernandez, M.I., Jimenez, M., Corral, T., and Pellicer, A. 2000. Cellular response to oncogenic ras involves induction of the Cdk4 and Cdk6 inhibitor p15(INK4b). Mol. Cell Biol. 20: 2915-2925.
34. Matsushime, H., Ewen, M.E., Strom, D.K., Kato, J.Y., Hanks, S.K., Roussel, M.F., and Sherr, C.J. 1992. Identification and properties of an atypical catalytic subunit (p34PSK-J3/cdk4) for mammalian D type G1 cyclins. Cell 71: 323-334.
35. Meyerson, M. and Harlow, E. 1994. Identification of G1 kinase activity for cdk6, a novel cyclin D partner. Mol. Cell Biol. 14: 2077-2086.
36. Moons, D.S., Jirawatnotai, S., Parlow, A.F., Gibori, G., Kineman, R.D., and Kiyokawa, H. 2002a. Pituitary hypoplasia and lactotroph dysfunction in mice deficient for cyclin-dependent kinase-4. Endocrinology 143: 3001-3008.
37. Moons, D.S., Jirawatnotai, S., Tsutsui, T., Franks, R., Parlow, A.F., Hales, D.B., Gibori, G., Fazleabas, A.T., and Kiyokawa, H. 2002b. Intact follicular maturation and defective luteal function in mice deficient for cyclin-dependent kinase-4 (Cdk4). Endocrinology 143: 647-654.
38. Nevins, J.R. 2001. The Rb/E2F pathway and cancer. Hum. Mol. Genet. 10: 699-703.
39. Ossovskaya, V.S., Mazo, I.A., Chernov, M.V., Chernova, O.B., Strezoska, Z., Kondratov, R., Stark, G.R., Chumakov, P.M., and Gudkov, A.V. 1996. Use of genetic suppressor elements to dissect distinct biological effects of separate p53 domains. Proc. Natl. Acad. Sci. 93: 10309-10314.
40. Pantoja, C. and Serrano, M. 1999. Murine fibroblasts lacking p21 undergo senescence and are resistant to transformation by oncogenic Ras. Oncogene 18: 4974-4982.
41. Pardee, A.B. 1989. G1 events and regulation of cell proliferation. Science 246: 603-608.
42. Pear, W.S., Nolan, G.P., Scott, M.L., and Baltimore, D. 1993. Production of high-titer helper-free retroviruses by transient transfection. Proc. Natl. Acad. Sci. 90: 8392-8396.
43. Pestell, R.G., Albanese, C., Reutens, A.T., Segall, J.E., Lee, R.J., and Arnold, A. 1999. The cyclins and cyclin-dependent kinase inhibitors in hormonal regulation of proliferation and differentiation. Endocr. Rev. 20: 501-534.
44. Pomerantz, J., Schreiber-Agus, N., Liegeois, N.J., Silverman, A., Alland, L., Chin, L., Potes, J., Chen, K., Orlow, I., Lee, H.W., et al. 1998. The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM27's inhibition of p53. Cell 92: 713-723.
45. Pruitt, K. and Der, C.J. 2001. Ras and Rho regulation of the cell cycle and oncogenesis. Cancer Lett. 171: 1-10.
46. Quelle, D.E., Zindy, F., Ashmun, R.A., and Sherr, C.J. 1995. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 83: 993-1000.
47. Rane, S.G., Cosenza, S.C., Mettus, R.V., and Reddy, E.P. 2002. Germ line transmission of the Cdk4(R24C) mutation facilitates tumorigenesis and escape from cellular senescence. Mol. Cell Biol. 22: 644-656.
48. Robles, A.I., Rodriguez-Puebla, M.L., Glick, A.B., Trempus, C., Hansen, L., Sicinski, P., Tennant, R.W., Weinberg, R.A., Yuspa, S.H., and Conti, C.J. 1998. Reduced skin tumor development in cyclin D1-deficient mice highlights the oncogenic ras pathway in vivo. Genes & Dev. 12: 2469-2474.
49. Rodriguez-Puebla, M.L., Miliani de Marval, P.L., LaCava, M., Moons, D.S., Kiyokawa, H., and Conti, J.C. 2002. CDK4 deficiency inhibits skin tumor development but does not affect normal keratinocyte proliferation. Am. J. Pathol. 161: 405-411.
50. Rowland, B.D., Denissov, S.G., Douma, S., Stunnenberg, H.G., Bernards, R., and Peeper, D.S. 2002. E2F transcriptional repressor complexes are critical downstream targets of p19(ARF)/p53-induced proliferative arrest. Cancer Cell 2: 55-65.
51. Sage, J., Mulligan, G.J., Attardi, L.D., Miller, A., Chen, S., Williams, B., Theodorou, E., and Jacks, T. 2000. Targeted disruption of the three Rb-related genes leads to loss of G(1) control and immortalization. Genes & Dev. 14: 3037-3050.
52. Schmitt, C.A., Fridman, J.S., Yang, M., Lee, S., Baranov, E., Hoffman, R.M., and Lowe, S.W. 2002. A senescence program controlled by p53 and p16(INK4a) contributes to the outcome of cancer therapy. Cell 109: 335-346.
53. Serrano, M., Gomez-Lahoz, E., DePinho, R.A., Beach, D., and Bar-Sagi, D. 1995. Inhibition of ras-induced proliferation and cellular transformation by p16INK4. Science 267: 249-252.
54. Serrano, M., Lee, H., Chin, L., Cordon-Cardo, C., Beach, D., and DePinho, R.A. 1996. Role of the INK4a locus in tumor suppression and cell mortality. Cell 85: 27-37.
55. Serrano, M., Lin, A.W., McCurrach, M.E., Beach, D., and Lowe, S.W. 1997. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 88: 593-602.
56. Sharpless, N.E. and DePinho, R.A. 1999. The INK4A/ARF locus and its two gene products. Curr. Opin. Genet. Dev. 9: 22-30.
57. -. 2002. p53: Good cop/bad cop. Cell 110: 9-12.
58. Sharpless, N.E., Bardeesy, N., Lee, K.H., Carrasco, D., Castrillon, D.H., Aguirre, A.J., Wu, E.A., Horner, J.W., and DePinho, R.A. 2001. Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigenesis. Nature 413: 86-91.
59. Sherr, C.J. 1998. Tumor surveillance via the ARF-p53 pathway. Genes & Dev. 12: 2984-2991.
60. Sherr, C.J. 2000. The Pezcoller lecture: Cancer cell cycles revisited. Cancer Res. 60: 3689-3695.
61. Sherr, C.J. and DePinho, R.A. 2000. Cellular senescence: Mitotic clock or culture shock? Cell 102: 407-410.
62. Sherr, C.J. and Roberts, J.M. 1999. CDK inhibitors: Positive and negative regulators of G1-phase progression. Genes & Dev. 13:1501-1512.
63. Soni, R., O'Reilly, T., Furet, P., Muller, L., Stephan, C., Zumstein-Mecker, S., Fretz, H., Fabbro, D., and Chaudhuri, B. 2001. Selective in vivo and in vitro effects of a small molecule inhibitor of cyclin-dependent kinase 4. J. Natl. Cancer Inst. 93: 436-446.
64. Soos, T.J., Kiyokawa, H., Yan, J.S., Rubin, M.S., Giordano, A., DeBlasio, A., Bottega, S., Wong, B., Mendelsohn, J., and Koff, A. 1996. Formation of p27-CDK complexes during the human mitotic cell cycle. Cell Growth Differ. 7: 135-146.
65. Sotillo, R., Dubus, P., Martin, J., de La, C.E., Ortega, S., Malumbres, M., and Barbacid, M. 2001. Wide spectrum of tumors in knock-in mice carrying a Cdk4 protein insensitive to INK4 inhibitors. EMBO J. 20: 6637-6647.
66. Stott, F.J., Bates, S., James, M.C., McConnell, B.B., Starborg, M., Brookes, S., Palmero, I., Ryan, K., Hara, E., Vousden, K.H., et al. 1998. The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. EMBO J. 17: 5001-5014.
67. Tsutsui, T., Hesabi, B., Moons, D.S., Pandolfi, P.P., Hansel, K.S., Koff, A., and Kiyokawa, H. 1999. Targeted disruption of CDK4 delays cell cycle entry with enhanced p27Kip1 activity. Mol. Cell Biol. 19: 7011-7019.
68. Weller, M. 1998. Predicting response to cancer chemotherapy: The role of p53. Cell Tissue Res. 292: 435-445.
69. Wolfel, T., Hauer, M., Schneider, J., Serrano, M., Wolfel, C., Klehmann-Hieb, E., De Plaen, E., Hankeln, T., Meyer, z.B.K., and Beach, D. 1995. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 269: 1281-1284.
70. Yu, Q., Geng, Y., and Sicinski, P. 2001. Specific protection against breast cancers by cyclin D1 ablation. Nature 411: 1017-1021.
71. Zarkowska, T. and Mittnacht, S. 1997. Differential phosphorylation of the retinoblastoma protein by G1/S cyclin-dependent kinases. J. Biol. Chem. 272: 12738-12746.
72. Zhang, Y., Xiong, Y., and Yarbrough, W.G. 1998. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 92: 725-734.
73. Zindy, F., Eischen, C.M., Randle, D.H., Kamijo, T., Cleveland, J.L., Sherr, C.J., and Roussel, M.F. 1998. Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes & Dev. 12: 2424-2433.
74. Zuo, L., Weger, J., Yang, Q., Goldstein, A.M., Tucker, M.A., Walker, G.J., Hayward, N., and Dracopoli, N.C. 1996. Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma. Nat. Genet. 12: 97-99.